Brain inflammation enhances 1-methyl-4-phenylpyridinium-evoked neurotoxicity in rats

Toxicology and Applied Pharmacology

Volumn 196, Issue 3, 2004, Pages 381-389

  Goralski, Kerry B ^a   Renton, Kenneth W ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

1 Methyl 4 phenylpyridinium (MPP+); 1 Methyl 4 phenyl 1,2,3,6 tetrahydropyridine (MPTP); Basal ganglia; CNS inflammation; Cytochrome P450; Kidney; Lipopolysaccharide; Liver; Parkinson's disease

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; BRAIN ENZYME; CYTOCHROME P450; DOPAMINE; LIPOPOLYSACCHARIDE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DRUG INDUCED DISEASE; ENCEPHALITIS; ENZYME METABOLISM; EVOKED RESPONSE; INFLAMMATION; INJECTION; KIDNEY; KIDNEY METABOLISM; LATERAL BRAIN VENTRICLE; LIVER; LUNG; MALE; MEDIAL FOREBRAIN BUNDLE; NEUROPATHOLOGY; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; RAT; RISK FACTOR;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; BRAIN; CYTOCHROME P-450 ENZYME SYSTEM; DOPAMINE AGENTS; INFLAMMATION; KIDNEY; LIPOPOLYSACCHARIDES; LIVER; LUNG; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 1942504005     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.taap.2003.12.022     Document Type: Article

References (55)

1. Ballard P.A., Tetrud J.W., Langston J.W. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology. 35:1985;949-956.
2. Barclay T.B., Peters J.M., Sewer M.B., Ferrari L., Gonzalez F.J., Morgan E.T. Modulation of cytochrome P-450 gene expression in endotoxemic mice is tissue specific and peroxisome proliferator-activated receptor-alpha dependent. J. Pharmacol. Exp. Ther. 290:1999;1250-1257.
3. Burke M.D., Thompson S., Elcombe C.R., Halpert J., Haaparanta T., Mayer R.T. Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologues: a series of substrates to distinguish between different induced cytochromes P-450. Biochem. Pharmacol. 34:1985;3337-3345.
4. Chinta S.J., Pai H.V., Upadhya S.C., Boyd M.R., Ravindranath V. Constitutive expression and localization of the major drug metabolizing enzyme, cytochrome P4502D in human brain. Brain Res., Mol. Brain Res. 103:2002;49-61.
5. Coleman T., Ellis S.W., Martin I.J., Lennard M.S., Tucker G.T. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4-implications for susceptibility to Parkinson's disease. J. Pharmacol. Exp. Ther. 277:1996;685-690.
6. Cummings B.S., Zangar R.C., Novak R.F., Lash L.H. Cellular distribution of cytochromes P-450 in the rat kidney. Drug Metab. Dispos. 27:1999;542-548.
7. Di Monte D.A., Lavasani M., Manning-Bog A.B. Environmental factors in Parkinson's disease. Neurotoxicology. 23:2002;487-502.
8. Fonne-Pfister R., Bargetzi M.J., Meyer U.A. MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylation. Biochem. Biophys. Res. Commun. 148:1987;1144-1150.
9. Forsyth J.T., Grunewald R.A., Rostami-Hodjegan A., Lennard M.S., Sagar H.J., Tucker G.T. Parkinson's disease and CYP1A2 activity. Br. J. Clin. Pharmacol. 50:2000;303-309.
10. Garcia Del Busto Cano E., Renton K. Modulation of hepatic cytochrome P450 during Listeria monocytogenes infection of the brain. J. Pharm. Sci. 92:2003;1860-1868.
11. Grunblatt E., Mandel S., Youdim M.B. MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson's disease: neuroprotective strategies. J. Neurol. 247(Suppl. 2):2000;II95-II102.
12. Grunblatt E., Mandel S., Maor G., Youdim M.B. Gene expression analysis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R-apomorphine. J. Neurochem. 78:2001;1-12.
13. Grundemann D., Liebich G., Kiefer N., Koster S., Schomig E. Selective substrates for non-neuronal monoamine transporters. Mol. Pharmacol. 56:1999;1-10.
14. Heikkila R.E., Manzino L., Cabbat F.S., Duvoisin R.C. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and several of its analogues on the dopaminergic nigrostriatal pathway in mice. Neurosci. Lett. 58:1985;133-137.
15. Heikkila R.E., Nicklas W.J., Duvoisin R.C. Dopaminergic toxicity after the stereotaxic administration of the 1-methyl-4-phenylpyridinium ion (MPP+) to rats. Neurosci. Lett. 59:1985;135-140.
16. Heikkila R.E., Nicklas W.J., Vyas I., Duvoisin R.C. Dopaminergic toxicity of rotenone and the 1-methyl-4-phenylpyridinium ion after their stereotaxic administration to rats: implication for the mechanism of 1-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine toxicity. Neurosci. Lett. 62:1985;389-394.
17. Imig J.D., Falck J.R., Inscho E.W. Contribution of cytochrome P450 epoxygenase and hydroxylase pathways to afferent arteriolar autoregulatory responsiveness. Br. J. Pharmacol. 127:1999;1399-1405.
18. Iravani M.M., Kashefi K., Mander P., Rose S., Jenner P. Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration. Neuroscience. 110:2002;49-58.
19. Ito O., Alonso-Galicia M., Hopp K.A., Roman R.J. Localization of cytochrome P-450 4A isoforms along the rat nephron. Am. J. Physiol. 274:1998;F395-F404.
20. Jimenez-Jimenez F.J., Tabernero C., Mena M.A., Garcia de Yebenes J., Garcia de Yebenes M.J., Casarejos M.J., Pardo B., Garcia-Agundez J.A., Benitez J., Martinez A.et al. Acute effects of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine in a model of rat designated a poor metabolizer of debrisoquine. J. Neurochem. 57:1991;81-87.
21. Karbach U., Kricke J., Meyer-Wentrup F., Gorboulev V., Volk C., Loffing-Cueni D., Kaissling B., Bachmann S., Koepsell H. Localization of organic cation transporters OCT1 and OCT2 in rat kidney. Am. J. Physiol., Renal, Fluid Electrolyte Physiol. 279:2000;F679-F687.
22. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 219:1983;979-980.
23. Langston J.W., Irwin I., Langston E.B., Forno L.S. 1-Methyl-4- phenylpyridinium ion (MPP+): identification of a metabolite of MPTP, a toxin selective to the substantia nigra. Neurosci. Lett. 48:1984;87-92.
24. LaVoie M.J., Hastings T.G. Peroxynitrite- and nitrite-induced oxidation of dopamine: implications for nitric oxide in dopaminergic cell loss. J. Neurochem. 73:1999;2546-2554.
25. Lohr J.W., Willsky G.R., Acara M.A. Renal drug metabolism. Pharmacol. Rev. 50:1998;107-141.
26. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
27. Mandel S., Grunblatt E., Youdim M. cDNA microarray to study gene expression of dopaminergic neurodegeneration and neuroprotection in MPTP and 6-hydroxydopamine models: implications for idiopathic Parkinson's disease. J. Neural Transm., Suppl. 2000;117-124.
28. Mandel S., Weinreb O., Youdim M.B. Using cDNA microarray to assess Parkinson's disease models and the effects of neuroprotective drugs. Trends Pharmacol. Sci. 24:2003;184-191.
29. McGeer E.G., McGeer P.L. Inflammatory processes in Alzheimer's disease. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 27:2003;741-749.
30. McGeer P.L., Yasojima K., McGeer E.G. Inflammation in Parkinson's disease. Adv. Neurol. 86:2001;83-89.
31. Morgan E.T. Regulation of cytochrome P450 by inflammatory mediators: why and how? Drug Metab. Dispos. 29:2001;207-212.
32. Morgan E.T., Li-Masters T., Cheng P.Y. Mechanisms of cytochrome P450 regulation by inflammatory mediators. Toxicology. 181-182:2002;207-210.
33. Nadeau S., Rivest S. Endotoxemia prevents the cerebral inflammatory wave induced by intraparenchymal lipopolysaccharide injection: role of glucocorticoids and CD14. J. Immunol. 169:2002;3370-3381.
34. Nicholson T.E., Renton K.W. Modulation of cytochrome P450 by inflammation in astrocytes. Brain Res. 827:1999;12-18.
35. Nicholson T.E., Renton K.W. Role of cytokines in the lipopolysaccharide- evoked depression of cytochrome P450 in the brain and liver. Biochem. Pharmacol. 62:2001;1709-1717.
36. Nicholson T.E., Renton K.W. The role of cytokines in the depression of CYP1A activity using cultured astrocytes as an in vitro model of inflammation in the central nervous system. Drug Metab. Dispos. 30:2002;42-46.
37. Ozaki N., Nakahara D., Mogi M., Harada M., Kiuchi K., Kaneda N., Miura Y., Kasahara Y., Nagatsu T. Inactivation of tyrosine hydroxylase in rat striatum by 1-methyl-4-phenylpyridinium ion (MPP+). Neurosci. Lett. 85:1988;228-232.
38. Pai K.S., Ravindranath V. Protection and potentiation of MPTP-induced toxicity by cytochrome P-450 inhibitors and inducer: in vitro studies with brain slices. Brain Res. 555:1991;239-244.
39. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1986;Academic Press, Sydney.
40. Perry T.L., Yong V.W., Jones K., Wall R.A., Clavier R.M., Foulks J.G., Wright J.M. Effects of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and its metabolite, N-methyl-4-phenylpyridinium ion, on dopaminergic nigrostriatal neurons in the mouse. Neurosci. Lett. 58:1985;321-326.
41. Perry V.H., Andersson P.B., Gordon S. Macrophages and inflammation in the central nervous system. Trends Neurosci. 16:1993;268-273.
42. Przedborski S., Jackson-Lewis V., Yokoyama R., Shibata T., Dawson V.L., Dawson T.M. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc. Natl. Acad. Sci. U.S.A. 93:1996;4565-4571.
43. Renton K.W. Hepatic drug metabolism and immunostimulation. Toxicology. 142:2000;173-178.
44. Renton K.W., Nicholson T.E. Hepatic and central nervous system cytochrome P450 are down-regulated during lipopolysaccharide-evoked localized inflammation in brain. J. Pharmacol. Exp. Ther. 294:2000;524-530.
45. Renton K.W., Dibb S., Levatte T.L. Lipopolysaccharide evokes the modulation of brain cytochrome P4501A in the rat. Brain Res. 842:1999;139-147.
46. Reynolds L.P., Allen G.V. A review of heat shock protein induction following cerebellar injury. Cerebellum. 2:2003;171-177.
47. Riedl A.G., Watts P.M., Brown C.T., Jenner P. P450 and heme oxygenase enzymes in the basal ganglia and their roles in Parkinson's disease. Adv. Neurol. 80:1999;271-286.
48. Scheld W.M., Koedel U., Nathan B., Pfister H.W. Pathophysiology of bacterial meningitis: mechanism(s) of neuronal injury. J. Infect. Dis. 186(Suppl. 2):2002;S225-S233.
49. Sewer M.B., Koop D.R., Morgan E.T. Differential inductive and suppressive effects of endotoxin and particulate irritants on hepatic and renal cytochrome P-450 expression. J. Pharmacol. Exp. Ther. 280:1997;1445-1454.
50. Shahi G.S., Das N.P., Moochhala S.M. Parkinson's disease and cytochrome P450: a possible link? Med. Hypotheses. 32:1990;277-282.
51. Upadhya S.C., Chinta S.J., Pai H.V., Boyd M.R., Ravindranath V. Toxicological consequences of differential regulation of cytochrome P450 isoforms in rat brain regions by phenobarbital. Arch. Biochem. Biophys. 399:2002;56-65.
52. Van Ess P.J., Pedersen W.A., Culmsee C., Mattson M.P., Blouin R.A. Elevated hepatic and depressed renal cytochrome P450 activity in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurochem. 80:2002;571-578.
53. Warner M., Kohler C., Hansson T., Gustafsson J.A. Regional distribution of cytochrome P-450 in the rat brain: spectral quantitation and contribution of P-450b,e, and P-450c,d. J. Neurochem. 50:1988;1057-1065.
54. Weissman J., Trevor A., Chiba K., Peterson L.A., Caldera P., Castagnoli N. Jr., Baillie T. Metabolism of the nigrostriatal toxin 1-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine by liver homogenate fractions. J. Med. Chem. 28:1985;997-1001.
55. Wullner U., Klockgether T. Inflammation in Parkinson's disease. J. Neurol. 250(Suppl. 1):2003;I35-I38.